Evidence map›Paper›PMID 32722754›Full record

GuidelineJournal of Crohn's & colitis2020

Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce.

F Magro, J-F Rahier, C Abreu, E MacMahon, A Hart, C J van der Woude, H Gordon, M Adamina, N Viget, S Vavricka and 5 more

Erratum issuedOpen access · bronzeAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal of Crohn's & colitis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 94 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Diarrhea and Coronavirus Disease 2019 Infection.Gastroenterology clinics of North America · 2023
    Review
  13. Article
  14. Article
  15. Review
  16. Perception of COVID-19 Pandemic Among IBD Clinicians and IBD Surgeons in Black Sea Region: A Cross-Sectional Questionnaire Study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022
    Article
  17. Review
  18. Article
  19. Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 14 institutions in 7 countries.

F MagroDepartment of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal; Department of Gastroenterology, Centro Hospitalar de São João, Porto, Portugal; Department of Clinical Pharmacology Centro Hospitalar de São João, Porto, Portugal.
J-F RahierCHU UCL Namur, Université catholique de Louvain, service de Hépato-gastroentérologie, Yvoir, Belgium.
C AbreuInfectious Diseases Service, Centro Hospitalar Universitário São João, Porto, Portugal; Instituto de Inovação e Investigação em Saúde (I3s), Faculty of Medicine, Department of Medicine, University of Porto, Portugal.
E MacMahonDepartment of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
A HartIBD Unit, St Mark's Hospital, London, UK.
C J van der WoudeDepartment of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlnads.
H GordonDepartment of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UKCentre for Immunobiology, The Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK.
M AdaminaDepartment of Surgery, Cantonal Hospital Winterthur, Winterthur, Switzerland.
N VigetDepartment of Infectious Diseases, Tourcoing Hospital, Tourcoing, France.
S VavrickaCenter for Gastroenterology and Hepatology, Zürich, Switzerland.
T KucharzikLüneburg Hospital, University of Hamburg, Department of Gastroenterology, Lüneburg, Germany.
S LeoneEFCCA, European Federation of Crohn's and Ulcerative Colitis Associations, Brussels, Belgium.
B SiegmundCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Berlin, Germany.
S DaneseDivision of Gastroenterology, IBD Center, Humanitas University, Rozzano, Milan, Italy.
L Peyrin-BirouletDepartment of Gastroenterology, Nancy University Hospital, Vandoeuvre-Les-Nancy, France.
Center for Pediatric Endocrinology Zurich · CHCentre Hospitalier de Tourcoing · FREuropean Federation of Nurses Associations · BEGuy's and St Thomas' NHS Foundation Trust · GBHumanitas University · ITHumboldt-Universität zu Berlin · DEi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTInserm · FRKantonsspital Winterthur · CHQueen Mary University of London · GBSt Mark's Hospital · GBUCLouvain · BEUniversidade do Porto · PTUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our knowledge of COVID-19 is changing and evolving rapidly, with novel insights and recommendations, almost on a daily basis. It behooves the medical community to provide updated information on a regular basis, on best practice to facilitate optimal care of infected patients and on appropriate advice for the general population. This is particularly important in the case of patients with chronic conditions, such as inflammatory bowel disease [IBD]. In this review, we have compiled existing evidence on the impact of COVID-19 in IBD patients and provide guidance on the most appropriate care to adopt during the pandemic. Our review highlights that IBD, per se, is not a risk factor for COVID-19. However, all IBD patients with symptoms should be tested for SARS-CoV-2 and the procedures for disease management should be carefully adapted: [i] in SARS-CoV-2-positive IBD patients, medical treatments should be re-evaluated [with a particular focus on corticosteroids] always with the purpose of treating active disease and maintaining remission; [ii] non-urgent surgeries and endoscopic procedures should be postponed for all patients; [iii] online consultancy should be implemented; and [iv] hospitalization and surgery should be limited to life-threatening situations.

Indexed as

BetacoronavirusClinical Laboratory TechniquesCoronavirus InfectionsCOVID-19COVID-19 TestingGlobal HealthHealth Care RationingHumansInfection ControlInflammatory Bowel DiseasesPandemicsPneumonia, ViralRisk AssessmentRisk FactorsSARS-CoV-2COVID-19covid managementinflammatory bowel diseaseSARS-CoV-2

Identifiers

PMID32722754
PMCPMC7454472
OpenAlexW3045809269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.